Gene Therapy Drama: 2nd Death Shakes Sarepta

Sarepta’s gene therapy for muscular dystrophy just hit another major snag—a second teen has died from liver injury after treatment. The company’s now pausing shipments for older, non-walking patients and rethinking safety protocols. The FDA might step in and tighten the rules or even pull the drug for some patients. Wild part? This one-time treatment costs $3.2 million. Wall Street’s freaking out, and Sarepta’s stock just tanked 42%. Stay tuned for more twists. #GeneTherapy #MuscularDystrophy #BiotechNews #Health #BodyHealth